Physician profile
Robert E Horn
NPI 1720066897
$3,032.93
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,227 · 2020: $186 · 2021: $987 · 2022: $633.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $1,012.20 | 2019-2022 | |
| Lundbeck LLC | $580.70 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $489.83 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $303.17 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $242.55 | 2019 | |
| Sunovion Pharmaceuticals INC. | $154.47 | 2019 | |
| Shire North American Group INC | $83.09 | 2019 | |
| Vanda Pharmaceuticals INC. | $60.72 | 2019 | |
| Abbvie INC. | $55.76 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.60 | 2022 | |
| Alkermes, INC. | $13.84 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Horn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.